In vitro activity of delafloxacin against highly levofloxacin-resistant invasive isolates of Streptococcus pneumoniae

Enferm Infecc Microbiol Clin (Engl Ed). 2022 Mar;40(3):131-133. doi: 10.1016/j.eimce.2020.09.009.

Abstract

Introduction: We report the activity of delafloxacin, a new fluoroquinolone with high affinity for both topoisomerase IV and DNA gyrase, against highly-levofloxacin-resistant invasive strains of Streptococcus pneumoniae.

Methods: A total of 173 highly-levofloxacin-resistant (MIC>32mg/L) S. pneumoniae invasive isolates were studied. The strains were isolated from blood (n=162) and other sterile fluids (n=11). Serotyping was performed by the Pneumotest-Latex and Quellung reaction. Delafloxacin, levofloxacin, penicillin, cefotaxime, erythromycin and vancomycin MICs were determined by the gradient diffusion method following EUCAST guidelines and breakpoints.

Results: Among the isolates, 32.9% were penicillin non-susceptible, 19.7% cefotaxime non-susceptible, and 76.9% erythromycin resistant. All were susceptible to vancomycin. Delafloxacin MIC50 and MIC90 (mg/L) values were 0.064 and 0.12, respectively; 60% (15/25) of serotype 9V isolates showed delafloxacin MICs≥0.12mg/L.

Conclusions: Delafloxacin was very active against highly-levofloxacin-resistant invasive isolates of S. pneumoniae. Isolates belonging to serotype 9V showed higher delafloxacin MIC values.

Keywords: Delafloxacin; Delafloxacino; Infecciones invasivas; Invasive infections; Streptococcus pneumoniae.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Fluoroquinolones / pharmacology
  • Levofloxacin* / pharmacology
  • Streptococcus pneumoniae*

Substances

  • Anti-Bacterial Agents
  • Fluoroquinolones
  • delafloxacin
  • Levofloxacin